Exosomes; Nano-Scale Bubbles Creating Waves in Diagnostics and
Therapeutics
How Companies Like Aethlon Medical, Life Technologies Corp and
Eli Lilly (in Partnership With Exosome Diagnostics) Are Working
With New Forms of Intercellular Communication to Change Personal
Medicine as We Know It
NEW YORK, NY and POINT ROBERTS, WA--(Marketwired - Dec 17, 2013)
- Investorideas.com, an investor news and research portal issues an
exclusive sector snapshot on the rapidly growing exosome market and
opportunities with key insight from Enal Razvi, Ph.D, Biotechnology
Analyst and Managing Director of SelectBio U.S.
For investors unfamiliar with exosomes, they are cell-derived
vesicles that are present in most biological fluids including blood
and urine, as well as other body fluids. Because the fluids
are easily accessible, they can be used as markers for disease
progression. Exosomes are described as tiny, nano-scale bubbles
that are released from cells capable of intercellular
communication.
"Only five years ago the principals of communicating within the
body were hormones, immunology or neurology and now we have found
another way of communicating and sending genetic signals between
cells," Life Technologies Corp.
So why is something so small creating such a huge buzz? Two key
significant areas of growth in the sector are diagnostics and
therapeutics for diseases such as cancer.
According to a report earlier this year from Select Biosciences,
"Exosome research is growing exponentially as researchers from
several disparate disciplines are exploring the role of exosomes in
inter-cellular communication, immunological responses, stem cell
behavior, cancer cell communication, etc. Indeed, the potential of
exosomes and other classes of microvesicles as a means of molecular
cargo transport is being intensively studied. "
Enal Razvi, Ph.D, Biotechnology Analyst and Managing Director of
SelectBio U.S, one of a few experts covering the space, shared
insight with Investorideas.com in a recent conversation.
When we asked Enal to discuss what publicly traded companies are
in this new sector for investors, he said there are only a few to
watch including Life Technologies Corp (LIFE) (currently being
acquired by Thermo Fisher Scientific), Eli Lilly (due to their
partnership with Exosome Diagnostics) and Aethlon Medical
(AEMD).
He went on to say, "Investors need to be aware of changes
exosomes allow, making companion diagnostics a reality. Exosomes
can create a paradigm shift for companion diagnostics based on
circulating biomarkers.
"Five years from now, or sooner, exosomes will become a key
diagnostic tool for cancers. If we don't know the origin of tumors;
biomarkers can narrow down the source.
Why investors should pay attention to the space is because
exosomes can significantly reduce the cost and increase the
compliance, primarily for cancer, and make biopsies for personal
medicine longitudinal sense. It becomes a very invasive
process for a patient to get ongoing biopsies, so this new method
of using exosomes for diagnostics is very exciting for
patients.
Currently the research market for exosomes is about $50 million
but this does not account for the opportunities in the diagnostics
space which will drive market growth and value creation."
Aethlon Medical (OTCBB: AEMD) is one of the only companies that
may be able to participate in both diagnostics and therapeutics in
the exosome space. The company recently announced the launch of
Exosome Sciences (ESI) as a subsidiary that is advancing
exosome-based strategies to diagnose and monitor the progression of
cancer, infectious disease and other life-threatening
conditions. Aethlon also attracted two of the best-known
thought leaders in the exosome industry to play key roles in the
new company.
"We are well positioned to benefit from the exosome revolution,"
stated Aethlon Medical Chairman and CEO, Jim Joyce. "We are
advancing patented first-in-class therapeutic technology to
eliminate the presence of tumor-secreted exosomes that trigger the
death of immune cells necessary for combating cancer. On the
diagnostic front, our Exosome Sciences research team pioneered the
field of exosome biology and is actively advancing a pipeline of
next generation diagnostic tools."
In September of this year, Exosome Diagnostics announced that it
entered into a collaboration agreement with Eli Lilly & Co.
"Exosome Diagnostics technology may provide a unique opportunity to
gain insight into the biology of complex conditions such as cancer
and immune disorders," stated Andrew Schade, Senior Medical
Director, Diagnostic and Experimental Pathology at Eli Lilly. He
further stated that "Exosome technology enables biofluid molecular
sampling and the ability to monitor disease progression in real
time. As Lilly explores new ways to pursue patient tailoring, we'll
continue to work with partners to expand our capabilities."
Another company in the space, stem cell therapy development
company ReNeuron reported in early December, "We have
highlighted a number of key developments in the period, notably the
successful and earlier-than-planned development of a
second-generation cryopreserved CTX drug product for our stroke and
critical limb ischaemia programmes, our planned world-class cell
manufacturing facility in South Wales, the granting of Orphan Drug
Designation for our retinitis pigmentosa programme and the
accelerated development of our CTX cell-based exosomes therapeutic
platform."
Life Technologies Corp has created a mini documentary
series entitled 'Exosomes-The Next Small Thing'. "Exosomes are a
very powerful way, a new way of how cells communicate long
distance... They are powerful mediators that carry all the
signaling and machinery necessary to change the behavior of the
neighboring cells."
http://www.lifetechnologies.com/ca/en/home/life-science/cell-analysis/exosomes/exosomes-documentary-episode-1.html
PDF for Exosomes Market Snapshot: Enal Razvi, Ph.D.
http://www.genengnews.com/media/pdf/GEN-Biomarket-Trends-Report-Exosomes%20Market-Landscape-2013.pdf
Bio for Enal Razvi, Ph.D- Biotechnology Analyst and Managing
Director of SelectBio U.S Enal Razvi, Ph.D., conducted his
doctoral work on viral immunology and subsequent to receiving his
Ph.D. went on to the Rockefeller University in New York to serve as
Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman
[Nobel Prize Winner in 2011 for his discovery of dendritic cells in
the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed
his research fellowship at Harvard Medical School. For the last two
decades Dr. Razvi has worked with small and large companies and
consulted for more than 100 clients worldwide. He currently serves
as Biotechnology Analyst and Managing Director of SelectBio U.S. He
can be reached at enal@selectbio.us
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address
life-threatening diseases. The Aethlon ADAPT™ (Adaptive
Dialysis-like Affinity Platform Technology) establishes the basis
for a new class of therapeutics that target the rapid elimination
of disease enabling particles from the circulatory system of
treated patients. The lead Aethlon ADAPT™ product is the
Hemopurifier®, a device that addresses a broad-spectrum of viral
pathogens as well as tumor-secreted exosomes that suppress the
immune system of cancer patients. Aethlon is also operating
under two government contracts with the Defense Advanced Research
Projects Agency (DARPA) related the development of a medical device
to reduce the incidence of sepsis. Exosome Sciences, Inc. is a
majority owned Aethlon subsidiary that is advancing exosome-based
strategies to diagnose and monitor cancer and infectious disease
progression. Additional information can be found at
www.AethlonMedical.com
News source:
http://www.hispanicbusiness.com/2013/12/4/reports_from_dalian_medical_university_advance.htm
About InvestorIdeas.com: InvestorIdeas.com is a global news
source for investors following leading business sectors including
biotech, tech, mining, mobile, energy, water, defense renewable
energy and Latin American stocks. Follow Investorideas.com on
Twitter http://twitter.com/#!/Investorideas Follow
Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at
http://www.linkedin.com/today/investorideas.com
Sign up for news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a
third party publisher of news and research as well as creates
original content as a news source. Original content created by
investorideas is protected by copyright laws other than syndication
rights. Investorideas is a news source on Google news and
Linkedintoday plus hundreds of syndication partners. Our site does
not make recommendations for purchases or sale of stocks or
products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment
involves risk and possible loss of investment. This site is
currently compensated by featured companies, news submissions,
content marketing and online advertising. Contact each company
directly for press release questions. Disclosure is posted on each
release if required but otherwise the news was not compensated for
and is published for the sole interest of our readers. More
disclaimer info:
http://www.investorideas.com/About/Disclaimer.asp Disclosure:
AEMD compensates Investorideas three thousand per month for news
and content publication and distribution
BC Residents and Investor Disclaimer: Effective September 15
2008 -- all BC investors should review all OTC and Pink sheet
listed companies for adherence in new disclosure filings and filing
appropriate documents with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must
adhere to regulations of each country.
Investorideas.com 800-665-0411 www.Investorideas.com
Grafico Azioni Atlas Copco (PK) (USOTC:ATLRF)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Atlas Copco (PK) (USOTC:ATLRF)
Storico
Da Mag 2023 a Mag 2024